Overexpression of tyrosine kinase receptors (RTKs), namely EGFR, PDGFR, VEGFR, and FGFR, and their ligands is among the most frequent alterations in glioma tumorigenesis, leading to aberrant activation of their downstream molecular pathways [18,59]. This evidence concerns the gene EGFR and central nervous system cancer.